The discovery of CDKs has had a transformative impact on cancer research. It has provided scientists with a deeper understanding of how cells proliferate and what goes wrong in cancer cells. This knowledge has led to the development of CDK inhibitors, a class of drugs that can block the activity of CDKs and thus potentially stop the growth of cancer cells. These inhibitors are now being tested in clinical trials and are showing promise as effective cancer treatments.
